clinical trial · NCT03340506
Dabrafenib and/or Trametinib Rollover Study
MelanomaNon Small Cell Lung CancerSolid TumorRare CancersHigh Grade Gliomadabrafenibtrametinib
brief summary
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.
started
Dec 28, 2017
primary completion
Dec 28, 2032
completion
Dec 28, 2032
last updated
Jun 10, 2026
official title
Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol